Physician profile
Shaw W Zhou
NPI 1740244565
$18,252.29
in general payments reported to CMS, 2019-2025
59 companies · $4,273 in 2025
The $4,273 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,232 · 2020: $793 · 2021: $3,426 · 2022: $2,917 · 2023: $1,977 · 2024: $2,634 · 2025: $4,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,370 · Consulting Fee: $1,420 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,370.06 |
| Consulting Fee | $1,420.00 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $4,993.49 | 2020-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $1,926.36 | 2021-2025 | Nuro, Interstim |
| Boston Scientific Corporation | $1,724.64 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml, Rezum Generator |
| Teleflex LLC | $1,514.04 | 2022-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $907.41 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $631.51 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $603.68 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $531.43 | 2020-2025 | Botox, Lupron Depot |
| Dendreon Pharmaceuticals LLC | $506.27 | 2019-2025 | Provenge |
| Pfizer INC. | $504.55 | 2019-2025 | |
| Coloplast Corp | $478.85 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $304.69 | 2020-2024 | Xiaflex, Aveed, Edex |
| Endo USA, INC. | $299.35 | 2024-2025 | Xiaflex, Aveed, Edex |
| Novartis Pharmaceuticals Corporation | $246.13 | 2022-2025 | |
| Palette Life Sciences, INC. | $237.52 | 2022 |
Show all 56 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaw Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.